NCT01931800

Completed

Identification and Quantification of Immune Response Induced...

Centre Hospitalier Universitaire Dijon Source

Compare

Other study identifiers

Sponsor study identifier

PIROTH PHRC R 2004

Study Type

observational

Actual enrollment (reported)

135

Locations

1 country

Sites

1

Timeline

Study Start

January 6, 2005

Actual (reported)

Primary Completion

January 27, 2015

Actual (reported)

Study Completion

January 27, 2015

Actual (reported)

Brief Summary

4 tubes (2 x7-ml dry tubes with yellow gelose, and 2 x 5 ml tubes with blue CTAD) will be taken from the patient within 24 hours following inclusion (D0) in the department in which the patient is hospitalised
4 tubes (2 x7-ml dry tubes with yellow gelose, and 2 x 5 ml tubes with blue CTAD) will be taken from the patient every 7 days following inclusion for 5 weeks (if the patient is still in hospital at the time), in the department where he/she is hospitalised (D7, D14, D21, D28, D35). Samples will no longer be taken once the patient has left the CHU, even if all of the samples have not been taken.
For children less than 6 years old, only 2 tubes (1 x 7 ml dry tube with yellow gelose, and 1x5 ml tube with blue CTAD) will be taken following the same timetable.
For hospitalised patients, a leeway of 48 hours is authorized for the sampling procedure. Samples will be taken at the same time samples are taken for the usual care of the patient.
The tubes will be taken to the Bacteriology Laboratory using the usual collection circuit of the CHU. These tubes will then be redirected to the Infectious Diseases Laboratory to be centrifuged and then stored at -80°C. The strain of Streptococcus pneumoniae isolated in the patient will be preserved at -80°C. If strains other than Streptococcus pneumoniae are isolated, these different strains will all be preserved at -80°C under the same identification number.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 135 participants
Study completion date: January 27, 2015
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 6, 2005
Actual (reported)
First Submitted
August 27, 2013
Actual (reported)
First Posted
August 29, 2013
Actual (reported)
Primary Completion
January 27, 2015
Actual (reported)
Study Completion
January 27, 2015
Actual (reported)

Last Updated: July 24, 2019
Status Verified: July 2019
Last Update Submitted: July 23, 2019

Conditions

Invasive Pneumococcic

Outcome Measures

Primary Outcomes (1)

Quantification of immune response induced by the hyaluronidase of Streptococcus pneumoniae
In the visit of inclusion then every 7 days during all the duration of patient hospitalization

Secondary Outcomes (1)

Quantification of hyaluronidase expression in strains of Streptococcus pneumoniae
In the visit of inclusion then every 7 days during all the duration of his hospitalization

Study Arms (3)

Presenting patients a pneumonia pneumococcique

Biological: Sampling of blood

Patients presenting a bacteremia pneumococcique

Biological: Sampling of blood

Patients affected by pneumococcique meningitis

Biological: Sampling of blood

Interventions

Sampling of bloodBiological

Patients affected by pneumococcique meningitisPatients presenting a bacteremia pneumococciquePresenting patients a pneumonia pneumococcique

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age1 Year+

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

All the patients hospitalized in a service, for whom a sampling "targets" (hémoculture, cerebrospinal fluid, bronchial brush, liquid of broncho-alveolar wash, protected tracheal aspiration) with positive culture to Streptococcus pneumoniae.

You may qualify if:

Patients (children or adults) hospitalised at Dijon CHU

Sponsors & Collaborators

Centre Hospitalier Universitaire Dijon
Otherlead

Study Sites (1)

CHU Dijon

Dijon, 21000, France

Enrollment

135 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 27, 2013

First Posted

August 29, 2013

Study Start

January 6, 2005

Actual (reported)

Unknown

NCT01573494

Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma

Not ApplicableCompleted

NCT02008552

Study of the Effect of the Benfluorex

Not ApplicableCompleted

Presenting invasive pneumococcal disease, confirmed by:

The presence of Streptococcus pneumoniae in a blood culture, or The presence of Streptococcus pneumoniae in a sample of cerebrospinal fluid, or The presence of significant levels of Streptococcus pneumoniae in an endobronchial sample (bronchial brushing or bronchoalveolar lavage), or in protected tracheal aspirations or in the spit of non-hospitalised patients or those in Intensive care Units.

Contact the study team to confirm eligibility.

Primary Completion

January 27, 2015

Actual (reported)

Study Completion

January 27, 2015

Actual (reported)

Last Updated

July 24, 2019

Record last verified: 2019-07

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01931800
Data provider: ClinicalTrials.gov
Source updated: 2019-07-24
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:35:22 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (3)

Presenting patients a pneumonia pneumococcique

Patients presenting a bacteremia pneumococcique

Patients affected by pneumococcique meningitis

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Enrollment

Study Design

Study Record Dates

Source record

Locations